IGM Biosciences Announces Retirement of Chairman Michael Loberg, Ph.D. from Board of Directors and Appointment of Elizabeth H.Z. Thompson, Ph.D. to Board of Directors
03 oct. 2023 16h05 HE
|
IGM Biosciences, Inc.
MOUNTAIN VIEW, Calif., Oct. 03, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies,...
IGM Biosciences to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
06 sept. 2023 07h00 HE
|
IGM Biosciences, Inc.
MOUNTAIN VIEW, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies,...
IGM Biosciences Announces Second Quarter 2023 Financial Results
03 août 2023 16h10 HE
|
IGM Biosciences, Inc.
– Continued progress in clinical development across portfolio –– Public equity offering and concurrent private placement with gross proceeds of $120.0 million – MOUNTAIN VIEW, Calif., Aug. 03, 2023 ...
IGM Announces Closing of Upsized Public Offering and Concurrent Private Placement and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
03 juil. 2023 16h01 HE
|
IGM Biosciences, Inc.
MOUNTAIN VIEW, Calif., July 03, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ: IGMS) today announced the closing of its previously announced upsized underwritten public offering of...
IGM Announces Pricing of $107.3 Million Upsized Public Offering and Concurrent Private Placement
22 juin 2023 07h58 HE
|
IGM Biosciences, Inc.
MOUNTAIN VIEW, Calif., June 22, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ: IGMS) today announced the pricing of its upsized underwritten public offering of 3,285,327 shares of its...
IGM Announces Proposed Public Offering and Concurrent Private Placement
21 juin 2023 17h17 HE
|
IGM Biosciences, Inc.
MOUNTAIN VIEW, Calif., June 21, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ: IGMS) today announced that it intends to offer and sell an aggregate of $100.0 million of shares of its common...
IGM Biosciences Announces Update on IGM-8444 Phase 1 Trial and Future Clinical Development
02 juin 2023 17h30 HE
|
IGM Biosciences, Inc.
– Additional data from Phase 1 combination with FOLFIRI continues to show encouraging activity in median third-line metastatic colorectal cancer patients – – Progression-free survival of 5.6 months...
IGM Biosciences to Present at the Jefferies Healthcare Conference
01 juin 2023 07h00 HE
|
IGM Biosciences, Inc.
MOUNTAIN VIEW, Calif., June 01, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies,...
IGM Biosciences Announces FDA Clearance to Begin Clinical Studies of Imvotamab in Lupus and Rheumatoid Arthritis
31 mai 2023 07h00 HE
|
IGM Biosciences, Inc.
MOUNTAIN VIEW, Calif., May 31, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, today...
IGM Biosciences to Host Conference Call and Webcast to Provide IGM-8444 Clinical Update
30 mai 2023 07h00 HE
|
IGM Biosciences, Inc.
– Event to be webcast live on Friday, June 2, 2023 at 7:00 p.m. ET – MOUNTAIN VIEW, Calif., May 30, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology...